IP Library Granted Patent US 8,501,467
Granted Patent B2
US 8,501,467 · App. 12/646,557 · Granted Aug 6, 2013

Cultures of GFAP

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,467
App. No.
12/646,557
Granted
Aug 6, 2013
Kind
B2
Abstract

Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.

Claims (25)

1. A suspension culture of GFAP + nestin + cells or GFAP + RC2 + cells, wherein said cells are substantially formed into cell aggregates, and wherein the cell aggregates are maintained in a culture medium containing a proliferation-inducing growth factor.

2. The culture of claim 1 , wherein the aggregated cells differentiate into neurons upon withdrawal of the proliferation-inducing growth factor.

3. The culture of claim 1 , wherein the proliferation-inducing growth factor is selected from the group consisting of epidermal growth factor, amphiregulin, basic fibroblast growth factor, acidic fibroblast growth factor, transforming growth factor alpha, leukemia inhibitor factor, ciliary neurotrophic factor and combinations thereof.

4. The culture of claim 2 , wherein the aggregated cells differentiate into neurons when plated on an adherent substrate.

5. The culture of claim 1 , wherein the proliferation-inducing growth factor is epidermal growth factor (EGF) and/or basic fibroblast growth factor (FGF-2).

6. The culture of claim 1 , wherein the cells are derived from the lateral ganglionic eminence (LGE) or medial ganglionic eminence (MGE) of a mammal.

7. The culture of claim 1 , wherein the cells are murine.

8. The culture of claim 1 , wherein the cells are human.

9. The culture of claim 1 , wherein fewer than 5% of the cells in the culture are β-tubulin III immunoreactive (β-tubulin III + ) under proliferation-promoting culture conditions and between 10-40% of the cells in the culture are β-tubulin III immunoreactive (β-tubulin III + ) under differentiation-inducing culture conditions.

10. The culture of claim 1 , wherein at least about 75% of cells are immunoreactive to GFAP + and nestin + .

11. The culture of claim 1 , wherein at least about 90% of cells are immunoreactive to GFAP + and nestin + .

12. The culture of claim 1 , wherein the culture medium further contains a serum.

13. A composition comprising GFAP + nestin + cells or GFAP + RC2 + cells, wherein said cells are substantially formed into cell aggregates.

14. The composition of claim 13 , wherein the cell aggregates are maintained in a culture medium containing a proliferation-inducing growth factor.

15. The composition of claim 14 , wherein the aggregated cells differentiate into neurons upon withdrawal of the proliferation-inducing growth factor.

16. The composition of claim 15 , wherein the aggregated cells differentiate into neurons when plated on an adherent substrate.

17. The composition of claim 14 , wherein the culture medium further contains a serum.

18. The composition of claim 13 , wherein the proliferation-inducing growth factor is selected from the group consisting of epidermal growth factor, amphiregulin, basic fibroblast growth factor, acidic fibroblast growth factor, transforming growth factor alpha, leukemia inhibitor factor, ciliary neurotrophic factor and combinations thereof.

19. The composition of claim 13 , wherein the proliferation-inducing growth factor is epidermal growth factor (EGF) and/or basic fibroblast growth factor (FGF-2).

20. The composition of claim 13 , wherein the cells are derived from the lateral ganglionic eminence (LGE) or medial ganglionic eminence (MGE) of a mammal.

21. The composition of claim 13 , wherein the cells are murine.

22. The composition of claim 13 , wherein the cells are human.

23. The composition of claim 13 , wherein fewer than 5% of the cells in the culture are β-tubulin III immunoreactive (β-tubulin III + ) under proliferation-promoting culture conditions and between 10-40% of the cells in the culture are β-tubulin III immunoreactive (β-tubulin III + ) under differentiation-inducing culture conditions.

24. The composition of claim 13 , wherein at least about 75% of cells are immunoreactive to GFAP + and nestin + or GFAP + and RC2 + .

25. The composition of claim 13 , wherein at least about 90% of cells are immunoreactive to GFAP + and nestin + or GFAP + and RC2 + .

Assignments (5)
SECURITY INTEREST Recorded Apr 22, 2019
From: BOCO SILICON VALLEY, INC.
To: BRIGHT OCEANS INTEL-TELECOM CO., LTD.
Reel/Frame 048958/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: STEMCELLS CALIFORNIA, INC.; STEMCELLS, INC.
To: BOCO SILICON VALLEY, INC.
Reel/Frame 042665/0877 →
SECURITY INTEREST Recorded Aug 16, 2016
From: STEMCELLS, INC.; STEMCELLS CALIFORNIA, INC.
To: ALPHA CAPITAL ANSTALT
Reel/Frame 039697/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2013
From: NSGENE A/S
To: STEMCELLS CALIFORNIA, INC.
Reel/Frame 029934/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: WAHLBERG, LARS; CAMPBELL, KENNETH; SKOGH, CHARLOTTA; ERIKSSON, CECILIA; WICTORIN, KLAS
To: NSGENE
Reel/Frame 024101/0947 →